Advancing women's health with a pioneering implant to treat breast cancer related lymphedema
European Journal of Internal Medicine · 2025-05 · 135 · 64-73
DOI: 10.1016/j.ejim.2025.01.027 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Internal Medicine, 2025-05. Verfasst von L Mazzolai und 9 weiteren Autor:innen. Beteiligte Einrichtung: Angiology Department, CHUV, Lausanne University Hospital and Lausanne University, Lausanne 1011, Switzerland. Electronic address: lucia.mazzolai@chuv…. Hauptthemen laut MEDLINE: Breast Cancer Lymphedema, Breast Neoplasms, Lymphedema, Prostheses and Implants. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: European Commission.
Abstract (Originalsprache)
Lymphedema (LE) is a globally recognized chronic and disabling condition with a high prevalence. At present, there is no curative treatment for LE, and management options are primarily limited to conservative approaches. To address this unmet need, we developed an innovative implantable device - the first-of-its-kind designed to replicate the function of lymphatic vessels in the affected limb. This novel device utilizes subcutaneous catheters and a micropump system to actively manage lymphatic fluid, representing a significant departure from traditional treatments. To evaluate feasibility, preliminary safety, and efficacy of this novel device, we conducted the first-in-human pilot study LymphoPilot. Nine patients with unilateral breast cancer-related LE (BCRL) underwent implantation of the device and discontinued conventional LE treatment. The device remained implanted for 8 weeks, during which its safety and efficacy were assessed. Results demonstrated no safety concerns and showed significant reductions in limb volume without the need for manual lymphatic drainage or compression treatment. These promising findings highlight the potential of this innovative approach and emphasize the need for further research into its long-term use as an alternative to current LE management strategies. This pioneering development offers hope for a transformative shift in LE treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Angiology Department, CHUV, Lausanne University Hospital and Lausanne University, Lausanne 1011, Switzerland. Electronic address: lucia.mazzolai@chuv.ch.
- Lymphatica Medtech SA, Lausanne, Switzerland.
- Angiology Department, CHUV, Lausanne University Hospital and Lausanne University, Lausanne 1011, Switzerland.
- Vascular Surgery Department, Lausanne University Hospital and Lausanne University, Lausanne, Switzerland.
Förderung
- European Commission
Zitieren
APA
Mazzolai, L., Triacca, V., Brochu-Vez, M. J., Boucard, V., Aberle, M., Chaplet, V., Ferrari, V., Déglise, S., Pisano, M., & Staubli, S. (2025). Advancing women's health with a pioneering implant to treat breast cancer related lymphedema. European Journal of Internal Medicine, 135, 64-73. https://doi.org/10.1016/j.ejim.2025.01.027
Vancouver
Mazzolai L, Triacca V, Brochu-Vez MJ, Boucard V, Aberle M, Chaplet V, et al. Advancing women's health with a pioneering implant to treat breast cancer related lymphedema. European Journal of Internal Medicine. 2025;135:64-73. doi:10.1016/j.ejim.2025.01.027
BibTeX
@article{Mazzolai2025,
author = {Mazzolai, L and Triacca, V and Brochu-Vez, M J and Boucard, V and Aberle, M and Chaplet, V and Ferrari, V and Déglise, S and Pisano, M and Staubli, S},
title = {Advancing women's health with a pioneering implant to treat breast cancer related lymphedema},
journal = {European Journal of Internal Medicine},
year = {2025},
volume = {135},
pages = {64--73},
doi = {10.1016/j.ejim.2025.01.027}
}
EUVIMED